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Seoul, KoreaGemcitabine has been considered a ﬁrst-line chemotherapy
agent for the treatment of pancreatic cancer. However, the
initial response rate of gemcitabine is low and chemoresistance
occurs frequently. Aptamers can be effectively internalized into
cancer cells via binding to target molecules with high afﬁnity
and speciﬁcity. In the current study, we constructed an ap-
tamer-based gemcitabine delivery system, APTA-12, and
assessed its therapeutic effects on pancreatic cancer cells
in vitro and in vivo. APTA-12 was effective in vitro and in vivo
in pancreatic cancer cells with high expression of nucleolin. The
results of in vitro cytotoxicity assays indicated that APTA-12
inhibited the growth of pancreatic cancer cell lines. In vivo eval-
uation showed that APTA-12 effectively inhibited the growth
of pancreatic cancer in Capan-1 tumor-bearing mice compared
to mice that received gemcitabine alone or vehicle. These re-
sults suggest that the gemcitabine-incorporated APTA-12 ap-
tamer may be a promising targeted therapeutic strategy for
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Pancreatic cancer is one of the most lethal tumors, and the prognosis
of pancreatic cancer has not improved despite recent developments in
cancer treatment. There were 48,960 newly diagnosed pancreatic can-
cer cases and 40,560 deaths recorded in the United States in 2015.1
Curative surgery is difﬁcult in most advanced pancreatic cancers,
and radiation therapy, conventional chemotherapy, and even targeted
chemotherapy have shown disappointing results when applied to
treat inoperable pancreatic cancers. The 5-year survival rate of
pancreatic cancer patients remains only 5%.2
Gemcitabine, a deoxycytidine analog, has been used as a standard
treatment for pancreatic cancer, but its response rate is very low.
Gemcitabine can be internalized into cancer cells via nucleoside
transporters, including human equilibrative nucleoside transporter
1 (hENT1) and human concentrative nucleoside transporters 1/3
(hCNT1/3).3 However, low expression levels of hENT1 and hCNT3
contribute to decreased efﬁcacy of gemcitabine and increased chemo-Molecular Therap
This is an open access article under the CC BY-NC-resistance.4,5 In addition, gemcitabine has low molecular weight and
high hydrophilicity and is easily degraded by cytidine deaminase,
leading to poor cellular penetration.6,7 To enhance the cellular uptake
of gemcitabine, drug delivery systems, including nanoparticle, lipo-
somes, albumin, and chitosan, have been broadly investigated.8
Aptamers are single-stranded oligonucleotides with highly speciﬁc
target binding afﬁnity that have been exploited in various ﬁelds. Ap-
tamers show three-dimensional (3D) folding, which results in high af-
ﬁnity to speciﬁc targets, similar to antibodies.9 Aptamers may have
the potential to substitute for antibodies because of their low immuno-
genicity and toxicity, thermal stability, large-scale production, and ease
of chemical synthesis and chemical modiﬁcation.10 Contrary to anti-
bodies, the smallmolecular weight of aptamers allows rapid renal excre-
tion, which displays a high target-to-background ratio in in vivo imag-
ing.11,12 Consequently, large numbers of aptamers have shown promise
as target-speciﬁc imaging agents.13 Despite these initial successful trials,
aptamer-based cancer therapy has been challenging. Indeed, few ap-
tamers have been reported to have antiproliferative effects against colon
cancer14 andErbB2-positivebreast cancer.15Rapiddistribution through
the bloodstream and renal excretion via the urinary tract can be an
advantage when aptamers are developed as diagnostic agents; however,
this can be a major pitfall with respect to therapy. Degradation by nu-
cleases in serum is another pitfall when aptamers are administered
intravenously. However, aptamers are still attractive therapeutic agents
because of their high target afﬁnity and unique advantages.
AS1411 is an aptamer with high guanine content that results in a
unique structure known as the G-quadruplex, which makes the 3Dy: Nucleic Acids Vol. 12 September 2018 ª 2018 The Authors. 543
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A B Figure 1. Binding Affinity and Stability of APTA-12
Aptamer
(A) Schematic representation of gemcitabine-incorpo-
rated APTA12 and determination of dissociation constant
(KD) values for the AS1411 and APTA-12 aptamers. (B)
Serum stability of APTA-12 and AS1411. The electro-
phoresis bands in the figure represent retained APTA-12
aptamer in 50% serum-containingmedia after incubation.
Molecular Therapy: Nucleic Acidsstructure relatively stable relative to other aptamers. AS1411 binds to
the cellular protein, nucleolin, which is known to be highly expressed
by cancer cells.16 This aptamer has been shown to have anticancer ef-
fects against many cancers; therefore, some clinical studies of AS1411
were initiated.17 However, the results of phase II clinical trials of
AS1411 were not good enough for it to be adopted as a ﬁrst-line ther-
apeutic agent.18
Recently, aptamer-drug conjugates (ApDCs) have been widely inves-
tigated in an attempt to overcome their poor cellular penetration,
nonspeciﬁc toxicity, and immunogenicity.10,19,21 When compared
with antibody-drug conjugates, development of ApDCs is easier
and more convenient because aptamers are synthesized via chemical
processes.22 In this study, we developed a gemcitabine-incorporated
AS1411, APTA-12, as an ApDC and demonstrated that the developed
compound has promising chemotherapeutic effects against pancre-
atic cancer.
RESULTS
Design and Binding Properties of APTA-12
The objective of the project was to deliver the cytotoxic anticancer
drug gemcitabine using oligonucleotide aptamers; thus, cell-type-spe-
ciﬁc internalization of the aptamer AS1411 was chosen as a model.
Gemcitabine, one of the most widely used chemotherapeutic drugs,
is a nucleoside deoxycytidine analog that can be incorporated into
an oligonucleotide.23,24 It has been reported that AS1411 forms a sta-
ble G-quadruplex structure and has the internal stem-loop structure
located between 12 and 15 nucleotides.25 APTA-12 aptamers were
created by single substitution of a guanine residue at position 14 of
the AS1411 sequence with a gemcitabine phosphoramidite (Fig-
ure 1A). The sequence of the APTA-12 aptamer was 50-GGT GGT
GGT GGT TZT GGT GGT GGT GG-30 (Z, gemcitabine). Gemcita-
bine was intentionally incorporated into the loop region of the
AS1411 aptamer to avoid altering the tertiary structure and protect
it from fast degradation by nucleases.
A previous report showed that the loop region of the G-quadruplex
played a key role in nucleolin binding, and chemical modiﬁcation
of the loop region could alter the protein-binding properties.26 To
evaluate the impact of internal incorporation of gemcitabine into544 Molecular Therapy: Nucleic Acids Vol. 12 September 2018the loop region, the equilibrium dissociation
constants (KD) of APTA-12 and AS1411 were
determined. The APTA-12 aptamer displayed
a similar binding afﬁnity with a KD value of14.37 ± 8.93 nM, and AS1411 showed a KD value of 16.36 ±
10.30 nM (Figure 1A). This result demonstrated that the gemcitabine
modiﬁcation of the loop region of the AS1411 sequence did not alter
the binding afﬁnity and that chemically modiﬁed APTA-12 retained a
slightly higher binding afﬁnity to nucleolin than the AS1411 aptamer.
Stability of APTA-12
To determine the stability of the APTA-12 aptamer, serum stability
assays were carried out by incubating the APTA-12 aptamers in hu-
man serum. As indicated in Figure 1B, APTA-12 and AS1411 ap-
tamers remained stable for up to 24 hr of incubation. It is known
that G-quadruplex-forming oligonucleotides are relatively stable
against nuclease degradation.27,28 The high serum stability of gua-
nine-rich APTA-12 can be explained by its stable G-quadruplex
structure.
In Vitro Characterization of APTA-12
To investigate the binding speciﬁcity of the APTA-12 aptamer,
pancreatic cancer cells were imaged by confocal microscopy after in-
cubation with Cy5-labeled APTA-12. H6c7 cells were used as a nega-
tive control to determine nonspeciﬁc binding. As shown in Figure 2A,
APTA-12 aptamers bound on the periphery of the Capan-1, AsPC-1,
andMIAPaCa-2 cells, while no aptamer binding was observed in con-
trol H6c7 cells. Capan-1 cells were treated with Cy5-labeled cytosine-
rich oligonucleotide (CRO), as a negative control. Cy5-CRO displayed
only a weak ﬂuorescence signals in Capan-1 cells (Figure S1A). To
further characterize the binding speciﬁcity of the APTA-12 aptamer
for pancreatic cancer cell lines, ﬂow cytometric analysis was carried
out using Cy5-labeled APTA-12. We found that APTA-12 aptamers
were able to bind to all three pancreatic cancer cell lines (Figure 2B).
Both APTA-12 and AS1411 aptamers had a relatively high afﬁnity
for Capan-1 cells (49.3% and 48.2% shift, respectively) compared to
control cells (1.4% and 1.2% shift, respectively). Moreover, APTA-
12 was shown to have much higher binding afﬁnity for Capan-1 cells
compared to negative control CRO (Figure S1B). These results suggest
that binding of APTA-12 aptamer was speciﬁc to nucleolin.
A previous study showed that AS1411 internalized into various can-
cer cell lines.17 To determine whether APTA-12 aptamers were inter-
nalized after binding to the cell-surface target, z stack images of
AB
Figure 2. In Vitro Characterization of Gemcitabine-Incorporated APTA-12 Aptamer
(A) Confocal microscopy images of Capan-1, AsPC-1, MIA PaCa-2 cells, and negative control H6c7 cells incubated with Cy5-labeled APTA-12 (red). The nuclei were stained
with DAPI (blue). (B) The specific binding capacity of APTA-12 to pancreatic cancer cells was assessed by flow cytometry. Nucleolin-positive Capan-1, MIA PaCa-2, and
AsPC-1 cell lines and nucleolin-negative H6c7 cells were stained with Cy5-AS1411 or Cy5-APTA-12.
www.moleculartherapy.orgCapan-1 and H6c7 cells were acquired. Confocal z stack images of
50-Cy5-APTA-12 over a 4-hr period showed that APTA-12 aptamers
were efﬁciently internalized into nucleolin-positive Capan-1 cells;
however, the aptamers were not internalized into the H6c7 cells (Fig-
ure 3). These results indicated that APTA-12 is able to deliver the
anticancer drugs or prodrugs selectively into target cells.
In Vivo Characterization of APTA-12
The ex vivo biodistribution of 18F-labeled APTA-12 was investigated
in Capan-1 tumor-bearing mice. The blood-pool uptake of
18F-hyAPTA-12 decreased from 1.42 ± 0.12 percent injected dose
per gram (%ID/g) at 30 min to 0.47 ± 0.09 %ID/g at 60 min after in-
jection (Figure 4A). Kidney uptake of 18F-hyAPTA-12 also drastically
decreased from 9.87 %ID/g at 30 min to 0.51 %ID/g at 60 min after
injection. The retention values for 18F-hyAPTA-12 in the blood and
tissues were quite similar to those for 18F-hyAS1411 (Figure 4B).
This result agreed with previous reports that aptamers were quickly
distributed through the bloodstream and rapidly eliminated via theurinary tract.11,12 The tumor uptake of 18F-hyAPTA-12 averaged
0.98 ± 0.11 %ID/g at 30 min after injection, which decreased to
0.51 ± 0.07 %ID/g at 60 min. Positron emission tomography (PET)
images were acquired at 60 min after injection of 18F-hyAPTA-12
and compared to 18F-hyAS1411. MicroPET imaging showed high up-
take of 18F-hyAPTA-12 in the liver, kidneys, and intestines, which
correlated with the biodistribution studies (Figure 4C). The tumor
uptake of 18F-hyAPTA-12 (0.62 ± 0.08 %ID/g, n = 3) was similar to
that of 18F-hyAS1411 (0.58 ± 0.11 %ID/g, n = 3) (Figure 4D).
Cell Cytotoxicity in Pancreatic Cancer Cell Lines
Previous reports showed that AS1411 aptamers have antiproliferative
activity against various cancer cell lines.29,30 And gemcitabine has a
broad spectrum of antitumor activity, including pancreatic can-
cer.31,32 To assess the potential cytotoxic effects of gemcitabine-incor-
porated APTA-12 aptamers on pancreatic cancer cells in vitro, IC50
values were determined. As indicated in Figure 5A, APTA-12 in-
hibited the growth of Capan-1, MIA PaCa-2, and AsPC-1 cells,Molecular Therapy: Nucleic Acids Vol. 12 September 2018 545
Figure 3. Representative Confocal Fluorescence Microscopy Z Stack Images of Capan-1 and H6c7 Cells Incubated with Cy5-Labeled APTA-12
Z stack images were acquired from the bottom to the top of the cells after 1 hr and 4 hr incubation of Cy5-APTA-12 (red) at 37C. Nuclei are stained with DAPI (blue).
Scale bars, 20 mm.
Molecular Therapy: Nucleic Acidswith IC50 values of 68.8 ± 4.2, 284.6 ± 73.8, and 204.4 ± 38.7 nM,
respectively. The lowest IC50 value of APTA-12 was found in
Capan-1 cells. The half-maximal inhibitory concentration (IC50)
values of APTA-12-treated Capan-1 cells were 43-fold lower than
AS1411-treated Capan-1 cells (IC50 = 2,961.3 ± 401.4 nM). Gemcita-
bine showed similar growth inhibition against pancreatic cancer cells.
The IC50 values for the normal cell H6c7 were 3.6 ± 0.3 nM for gem-
citabine and 147,450.0 ± 7,141.8 nM for AS1411. In this study,
Capan-1 cells were chosen for further in vivo studies because of their
high receptor-binding afﬁnity and high sensitivity to the cytotoxic ef-
fects of APTA-12.
Antitumor Efficacy of APTA-12 In Vivo
The antitumor efﬁcacy of APTA-12 was investigated using Capan-1
tumor xenograft models. Tumors from vehicle-treated mice showed
a 6.9-fold increase in size during the treatment schedule. Tumors in
mice treated with gemcitabine alone at 6 mg/kg grew slowly to about
2.4 times their initial size (Figure 5B). However, mice injected with
100 mg/kg APTA-12 exhibited approximately 93.4% tumor growth
inhibition when compared to control mice injected with Dulbecco’s
PBS (DPBS) alone and a 42.5% tumor shrinkage compared to the tu-
mor size at the beginning of treatment (Figure 5C). The average tu-
mor weight of the APTA-12-treated group was signiﬁcantly reduced
compared to tumors of the AS1411- or vehicle-treated groups
(unpaired t test; p < 0.01). In addition, 100 mg/kg APTA-12 had a
stronger antitumor effect compared with 6 mg/kg gemcitabine
(p < 0.05) (Figure 5D).546 Molecular Therapy: Nucleic Acids Vol. 12 September 2018The body weight of mice was monitored during the treatment. The
weight loss of the mice treated with gemcitabine or APTA-12 did
not exceed 10% of their initial body weight (Figure 5E). The mean
weight in the 100 mg/kg APTA-12-treated group was 22.5 ± 0.5 g
and was not different from that of the 100 mg/kg AS1411-treated
group (22.7 ± 0.7 g) or 6 mg/kg gemcitabine-treated group (22.9 ±
0.6 g). To evaluate potential toxicity of APTA-12, peripheral red
blood cell (RBC) and white blood cell (WBC) counts were measured.
There was no signiﬁcant difference in the levels of RBC andWBC be-
tween the gemcitabine-, AS1411-, APTA-12-, and vehicle (DPBS)-
treated groups (Table 1). To investigate the effects of APTA-12 on
liver and kidney function, blood levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP),
blood urea nitrogen (BUN), and creatinine were determined. There
were no signiﬁcant differences in serum biochemical values between
the APTA-12-treated group and the vehicle-treated group (pR 0.05)
(Table 2). This result suggested that APTA-12 treatment caused no
major toxicity or side effects.
To evaluate the therapeutic effect of APTA-12, 18F-ﬂuorodeoxyglu-
cose (18F-FDG) PET was performed at the end of treatment. The
microPET quantiﬁcation in APTA-12-treated mice showed a clear
reduction in the mean standardized uptake value (SUVmean)
compared to the vehicle-treated mice (Figure S2A). The SUVmean of
tumors was 0.29 ± 0.03 for the APTA-12 (100 mg/kg)-treated group
and 1.32 ± 0.06 for vehicle-treated group, which were signiﬁcantly
different (unpaired t test, p < 0.001) (Figure S2B). 18F-FDG PET
DA B
C
Figure 4. In Vivo Characterization of F-18-Labeled
APTA-12 in Capan-1 Tumor-Bearing Mice
Quantitative analysis of biodistribution of (A) 18F-hyAPTA-
12 aptamer and (B) 18F-hyAS1411 aptamer. Mice were
sacrificed at 30 min and 60 min after injection with 300
pmol of 18F-hyAPTA-12 or 18F-hyAS1411 (n = 4, at each
concentration). The radioactivity was expressed as%ID/g.
(C) Representative PET images at 60 min after injection of
18F-hyAPTA-12 or 18F-hyAS1411. The red-dotted circles
indicate Capan-1 tumors. (D) Quantification analysis of
18F-labeled APTA-12 and AS1411 accumulation in
Capan-1 tumors derived from the PET images at 60 min
after injection. The radioactivity was expressed as %ID/g.
www.moleculartherapy.orgimaging conﬁrmed that tumor growth in APTA-12-treated mice was
markedly inhibited compared to the control group.
Cell apoptosis and proliferation in tumors were analyzed by H&E,
TUNEL, and Ki67 assay (Figure 6). H&E staining of tumor sections
from the vehicle-treated group showed a greater number of mitotic
cells than the APTA-12-treated group. APTA-12 induced at least a
4-fold increase in the number of TUNEL-positive apoptotic cells
compared to vehicle (p < 0.05). Cell proliferation was evaluated by
Ki67 immunostaining. The numbers of Ki67-positive cells in the tu-
mors of the APTA-12 (100 mg/kg)-treated group were 3.7-fold lower
than the vehicle-treated group (p < 0.05). These results indicated that
APTA-12 at a therapeutic dosage efﬁciently inhibited in vivo tumor
growth in Capan-1 tumor-bearing mice.
DISCUSSION
Here, we report the characterization of the gemcitabine-incorporated
aptamer, APTA-12, which exhibited potent antitumor activity in
pancreatic cancer cells. APTA-12, which binds to nucleolin with
high afﬁnity, showed antiproliferative activity in pancreatic cancer
cells in vitro. In addition, APTA-12 signiﬁcantly inhibited tumor
growth in Capan-1 tumor-bearing mice in vivo.
The clinical use of anticancer drugs is limited by their general toxicity
to proliferating cells and low selectivity.33 Therefore, there has been
an effort to develop new anticancer agents that are highly effective
and less toxic. Since the discovery that a short antisense oligodeoxy-
nucleotide could inhibit RNA translation and replication of the Rous
sarcoma virus in 1978, therapeutic oligonucleotides including anti-
sense oligonucleotides, RNA interference, decoy oligonucleotides,
and aptamers have been extensively investigated and applied to theMolecular Therapy: Nucleic Acids Vol. 12 September 2018 547l
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ttreatment of various cancers.34–37 Previous
studies have shown that guanine-rich oligonu-
cleotides (GROs) bind to speciﬁc cellular pro-
teins and inhibit the proliferation of various
cancer cells.38 GROs can form stable G-quadru-
plex structures because three to four guanine
bases form a square planar structure called a
G-quartet through Hoogsteen base pairing,
and these G-quartets spontaneously assembleinto four-stranded helical structures termed G-quadruplexes.39,40
The major disadvantage in the use of oligonucleotides in clinical ap-
plications is metabolic lability, rapid systemic clearance, and low cel
permeability.41,42 However, oligonucleotides that form G-quadru-
plexes display relatively higher cell permeability, thermostability
and nuclease resistance than non-G-quartet-forming oligonucleo-
tides.18,38,39 One of themost widely studied G-quadruplex forming ol-
igonucleotides is DNA aptamer AS1411. Aptamers are relatively shor
(20–60 nucleotides) single-stranded oligonucleotides capable of bind-
ing to their target molecules through structural recognition-like anti-
bodies.43,44 AS1411 can bind to nucleolin that is overexpressed on the
surface of cancer cells and then be internalized into the cytoplasm and
nucleus, where it exerts antiproliferative effects through inhibition o
nuclear factor-kB (NF-kB) signaling or destabilization of bcl-2
mRNA.29,45 AS1411 has also been investigated for its potential useful-
ness in the delivery of anticancer drugs.46–48 Trinh et al.48 assessed the
antitumor efﬁcacy of doxorubicin-conjugated AS1411t and found
that the AS1411-doxorubicin adduct could efﬁciently deliver doxoru-
bicin into target cells and inhibit tumor growth without inducing
apoptosis.
The main objective of the present study was to develop a method for
delivery of the anticancer drug gemcitabine using an oligonucleotide
aptamer and evaluate its in vivo antitumor efﬁcacy against pancre-
atic tumors. Gemcitabine is a deoxycytidine analog that inhibits
DNA synthesis via incorporation of its diphosphate metabolite
into the DNA strand. Recent studies showed that chemically modi-
ﬁed AS1411 aptamer signiﬁcantly improved targeting afﬁnity and
inhibition of cancer cell proliferation.25,49 We hypothesized tha
gemcitabine could be incorporated into nucleolin-targeting ap-
tamers and internalized into tumor cells after binding to cell-surface
AB
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Figure 5. Therapeutic Efficacy of Gemcitabine-Incorporated APTA-12 Aptamer against Pancreatic Cancer Cells
(A) IC50 values of gemcitabine-, AS1411-, and APTA-12-treated pancreatic cell lines (Capan-1, MIA PaCa-1, AsPC-1) and normal cell (H6c7) after 6 days treatment at various
concentrations (0.00001–1,000 mM). (B) The growth curves of Capan-1 tumor-bearing mice treated with intravenous injections of gemcitabine (6 mg/kg), AS1411
(100 mg/kg), APTA-12 (100 mg/kg), or vehicle (DPBS) alone. (C) Representative image of tumors excised on day 22. (D) Changes in mean tumor weight and (E) the body
weights of mice treated with gemcitabine, AS1411, APTA-12, and vehicle. Data are presented as the mean ± SD. *p < 0.05; **p < 0.01.
Molecular Therapy: Nucleic Acidsnucleolin. The internalized gemcitabine-incorporated AS1411 then
exerted therapeutic effects through destabilization of bcl-2 mRNA
and incorporation of gemcitabine into DNA after degradation by
nuclease. With this in mind, a gemcitabine-modiﬁed G-quadru-
plex-forming oligonucleotide, APTA-12, was designed and synthe-
sized based on the AS1411 aptamer. To verify the hypothesis, the548 Molecular Therapy: Nucleic Acids Vol. 12 September 2018nucleolin-binding afﬁnity and serum stability of APTA-12 were
evaluated. The measured KD values and in vitro serum stability of
APTA-12 were comparable to those of the AS1411 aptamer. We
also demonstrated that APTA-12 could efﬁciently deliver gemcita-
bine into pancreatic cancer cells. In the confocal image of
Capan-1, AsPC-1, and MIA PaCa-2 cells, APTA-12 aptamers
Table 1. Comparison of Hematological Values between Gemcitabine-,
AS1411-, and APTA-12-Treated Mice (Mean ± SD)
Parameters Control
Gemcitabine
6 mg/kg
AS1411
100 mg/kg
APTA-12
100 mg/kg
Red blood cell (M/mL) 10.5 ± 0.3 10.2 ± 0.5 9.8 ± 0.5 9.8 ± 0.6
Hematocrit (%) 59.6 ± 2.0 57.4 ± 2.5 54.1 ± 3.6 58.8 ± 4.6
Mean corpuscular
volume (fL)
54.4 ± 1.2 56.2 ± 0.6 55.3 ± 0.8 60.2 ± 2.0
Mean cell
hemoglobin (pg)
13.7 ± 0.5 12.2 ± 2.9 7.7 ± 8.8 14.5 ± 0.5
Mean cell hemoglobin
concentration (g/dL)
25.1 ± 0.6 21.8 ± 5.0 26.0 ± 1.5 24.1 ± 0.4
White blood
cell (k/mL)
0.9 ± 0.2 0.8 ± 0.2 0.7 ± 0.5 1.7 ± 0.4
Neutrophil (k/mL) 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.2 0.6 ± 0.2
Lymphocyte (k/mL) 0.6 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 0.9 ± 0.2
Monocyte (k/mL) 0.1 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.2 ± 0.1
Eosinophil (k/mL) 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.0 ± 0.0
Basophil (k/mL) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
www.moleculartherapy.orgwere selectively bound to the cell surface. z stack imaging showed
that internalized APTA-12 aptamers accumulated only in nucleo-
lin-positive cells, while ﬂow cytometric analysis demonstrated that
the APTA-12 aptamer had similar or higher afﬁnity to nucleolin
protein than the AS1411 aptamer. Furthermore, APTA-12 treat-
ment of pancreatic cancer cells signiﬁcantly reduced cell prolifera-
tion and the IC50 value of APTA-12-treated cells was much lower
than that of the AS1411-treated cells. In vivo evaluation showed
that APTA-12 effectively inhibited the growth of pancreatic cancer
cells in nude mice. [18F]FDG SUVmean in the tumor region of the
APTA-12-treated mice decreased by 78% when compared to the
vehicle-treated mice. No signiﬁcant differences in body weights
were noted among treatment groups. TUNEL and Ki67 assay
showed that APTA-12 induced more apoptotic cell death and
reduced the numbers of proliferating tumor cells compared to the
control group. Taken together, these results demonstrated the anti-
tumor efﬁcacy of gemcitabine-incorporated APTA-12.
Various types of ApDCs have been developed to efﬁciently deliver
anticancer drugs to target sites.21,50 Typically, chemotherapy drugs
can be conjugated to aptamers via functional linkers or physical inter-
calation.21 In this study, single gemcitabine was chemically incorpo-
rated into the loop region of the DNA aptamer AS1411 without using
linkers or physical intercalation. The concept of intrinsic incorpora-
tion of gemcitabine into oligonucleotide was ﬁrst reported by Ray
et al.51 In their study, gemcitabine was incorporated into oligonucle-
otides by mutant RNA polymerases, and gemcitabine-containing
oligonucleotides were annealed to the aptamer for targeted drug
delivery. Recently, Yoon et al.52 synthesized gemcitabine or 5-ﬂuoro-
uracil-incorporated RNA aptamer and showed that it was internal-
ized and inhibited cell proliferation of pancreatic cancer cells
in vitro. Intrinsic incorporation of oncolytic nucleoside analog intoaptamers might be a good strategy for the development of ApDCs
because of easy chemical modiﬁcation without loss of afﬁnity and
large-scale chemical synthesis. In the present study, we demonstrate
that gemcitabine-incorporated APTA-12 exerted growth-inhibitory
properties against different pancreatic cancer cell lines and possessed
a higher therapeutic effect than gemcitabine alone in in vivo. These
results suggest that aptamer-based gemcitabine delivery of APTA-
12 is a promising anticancer strategy for targeted pancreatic cancer
therapy.
MATERIALS AND METHODS
Cell Lines and Reagents
The human pancreatic cancer cell lines Capan-1, AsPC-1, and MIA
PaCa-2 were purchased from the American Type Culture Collection
(Manassas, VA, USA). Noncancerous human pancreatic duct epithe-
lial cell line HPDE6-C7 (H6c7) was purchased from Kerafast (Boston,
MA, USA). Cells were grown in RPMI medium (Capan-1 and
AsPC-1) or DMEMmedium (MIA PaCa-2) supplemented with peni-
cillin G (100 U/mL), streptomycin (100 mg/mL), and 10% fetal bovine
serum (FBS). H6c7 cells were maintained in keratinocyte serum-free
media supplemented with epidermal growth factor and bovine pitu-
itary extract (Life Technologies, Grand Island, NY). All cells were
incubated at 37C in a humidiﬁed incubator with 5% CO2/95% air.
Cell culture media, supplements, and serum products were purchased
from Invitrogen (Carlsbad, CA, USA). AS1411, APTA-12, CRO,
50-Cy5-AS1411 and 50-Cy5-APTA-12 aptamers were synthesized in
house. All reagents were commercially available and used without
modiﬁcation.
Synthesis of Aptamers
All aptamers were synthesized using a commercial DNA synthesizer
(PolyGen, Langen, Germany) following the standard phosphorami-
dite method.53 The AS1411 sequence was 50-GGT GGT GGT GGT
TGT GGT GGT GGT GG-30, and the APTA-12 sequence was
50-GGT GGT GGT GGT TZT GGT GGT GGT GG-30 (Z, gemcita-
bine). CRO (50-CCT CCT CCT CCT TCT CCT CCT CCT CC-30)
was synthesized as a negative control. A 0.1 M solution of phosphor-
amidites in anhydrous acetonitrile was used for the synthesis. Gemci-
tabine phosphoramidite was prepared by a modiﬁcation of the
previously reported procedure.51 Cy5 was coupled to the 50 termini
of AS1411, APTA-12, and CRO. Crude oligonucleotides were puriﬁed
using a 1260 Inﬁnity II reversed-phase high-performance liquid chro-
matograph (Agilent Technologies, Santa Clara, CA, USA) on an
XTerra RP18 column (10 mm, 7.8  300 mm, Waters, Milford,
MA, USA). The eluent was acetonitrile containing 0.1 M triethylam-
monium acetate buffer. The resulting product was characterized by
LCMS-2020 (Shimadzu, Kyoto, Japan), and the purity was assessed
using the 1260 Inﬁnity II LC system.
Nucleolin-Binding Assay
Nucleolin protein was purchased from Vaxron (Rockaway, NJ, USA).
The afﬁnity of nucleolin for AS1411 and APTA-12 was assessed ac-
cording to the modiﬁed method of Carballo et al.54 The 50 termini
of AS1411 and APTA-12 were labeled with phosphorus-32 (32P)Molecular Therapy: Nucleic Acids Vol. 12 September 2018 549
Table 2. Serum Biochemical Values of Mice Treated with Gemcitabine, AS1411, and APTA-12 (Mean ± SD)
Parameters Control Gemcitabine 6 mg/kg AS1411 100 mg/kg APTA-12 100 mg/kg
Alanine aminotransferase (U/L) 25.5 ± 2.1 33.0 ± 1.4 34.5 ± 3.5 28.5 ± 7.8
Aspartate aminotransferase (U/L) 128.5 ± 27.6 233.0 ± 7.1 194.0 ± 63.6 174.0 ± 89.1
Alkaline phosphatase (U/L) 215.0 ± 9.9 177.0 ± 15.6 131.0 ± 9.9 230.0 ± 12.7
Blood urea nitrogen (mg/dL) 22.2 ± 2.3 16.3 ± 0.0 10.2 ± 1.2 16.4 ± 1.0
Creatinine (mg/dL) 0.2 ± 0.1 0.1 ± 0.0 0.2 ± 0.1 0.1 ± 0.0
Molecular Therapy: Nucleic Acidsusing [g-32P]-ATP (cat. #NEG502A; PerkinElmer, Waltham, MA,
USA) and T4 polynucleotide kinase (cat. #M0201L; New England
Biolabs, Ipswitch, MA, USA) at 37C for 30 min. Unincorporated
[g-32P]-ATP was removed using MicroSpin G-25 Columns (GE
Healthcare, Buckinghamshire, UK). For the afﬁnity assay, 32P-labeled
AS1411 and APTA-12 were incubated with nucleolin protein at
various concentrations at 37C for 15 min. Bound complexes were
mixed with Zorbax PSM-300 resin (Agilent Technologies) and
captured on a Durapore ﬁlter (Millipore, Bedford, MA). Filter plates
were exposed overnight and quantitated on a FLA-5100 (Fuji, Düssel-
dorf, Germany). Dissociation constant (KD) and maximal binding
(Bmax) were calculated using SigmaPlot10 (Systat Software, San Jose
CA, USA).
In Vitro Stability
AS1411 and APTA-12 were incubated with H4522 serum (Human
AB serum, Sigma-Aldrich, St. Louis, MO, USA) at a ﬁnal concentra-
tion of 50% and incubated at 37C for 0, 1, 2, 4, 8, and 24 hr. At each
time point, a sample was taken and quick-frozen by placement in a
deep freezer. Prior to analysis, samples were quickly thawed at
37C and diluted with water and PCI (phenol-chloroform-isoamyl
alcohol) solution. The mixtures were centrifuged at 10,000  g for
15 min, and supernatants were used for PAGE analysis. Gels were
stained with 0.5% methylene blue solution to reveal the oligonucleo-
tide aptamers.
Confocal Fluorescence Microscopy
Capan-1, AsPC-1,MIA PaCa-2, andH6c7 cells were grown on 3.5-cm
glass-bottom dishes (MatTek Corporation, Ashland, MA, USA). To
stain the plasma membrane and cytoplasmic nucleolin, the cells
were ﬁxed for 20min at room temperature in PBS containing 4%para-
formaldehyde. The cells were incubated with 200 nM of 50-Cy5-
APTA-12 in binding buffer (DPBS supplemented with 4.5 g/L glucose,
5 mMMgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL BSA) at 4Cwith
gentle rocking, and then washed three times with ice-cold PBS.
Confocal images were obtained using a Zeiss LSM-700 confocal
laser-scanning microscope (Carl Zeiss, Oberkochen, Germany).
For confocal z stack imaging, Capan-1 and H6c7 cells were treated
with 200 nM of 50-Cy5-APTA-12 and then incubated at 37C in
5% CO2 for 30 min, 1 hr, 2 hr, and 4 hr. At the indicated time points,
the cells were washed with binding buffer and ﬁxed with 4% parafor-
maldehyde. Confocal z stack images were acquired using a Zeiss LSM
770 and processed with ZEN 2010 image software.550 Molecular Therapy: Nucleic Acids Vol. 12 September 2018Flow Cytometry
Capan-1, AsPC-1, MIA PaCa-2, and H6c7 cells were incubated with
200 pmol of 50-Cy5-AS1411 or 50-Cy5-APTA-12 at 4C for 30 min in
binding buffer. Cells were then washed twice with PBS, and ﬂow
cytometric analyses were performed on an LSR II ﬂow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA).
Cell Viability Assays
Cytotoxicity of gemcitabine, AS1411, and APTA-12 was evaluated us-
ing a cell-proliferation reagentWST-1 (Roche Applied Science, Indian-
apolis, IN,USA) according to themanufacturer’s speciﬁcations. Inbrief,
Capan-1,AsPC-1,MIAPaCa-2, andH6c7 cellswere seeded into 96-well
plates at a density of 1 104 cells per well and incubated at 37C in 5%
CO2. After 24 hr, the media was removed and replaced with fresh me-
dium containing 5% FBS. The cells were treated with different concen-
trations (0.00001–1,000 mM) of gemcitabine (Sigma-Aldrich, cat.
#G6423), AS1411, or APTA-12 and then incubated at 37C for
6 days. All experiments were performed in triplicate. Cell viability was
measured, and the IC50 was obtained from the dose-response curve us-
ing GraphPad PRISM (GraphPad Software, San Diego, CA, USA).
Animal Model
Athymic female nudemice were purchased fromOrient Bio (Gyeong-
gido, South Korea). The animal experiments were performed with the
approval of the Institutional Animal Care and Ethics Committee of
Yonsei Laboratory Animal Research Center. For the tumor model,
a suspension of 1 106 Capan-1 cells in PBS was injected subcutane-
ously in the right thigh of 7-week-old BALB/c nude mice.
Biodistribution Study
For the biodistribution study, 18F-hyAS1411 or 18F-hyAPTA-12 was
synthesized as previously described.12 Capan-1 tumor-bearing mice
were anesthetized with 2% isoﬂurane and injected intravenously
with radiotracer 18F-hyAPTA-12 (3.7 ± 0.2 megabecquerel [MBq],
300 pmol) via the tail vein. Mice were sacriﬁced at 30 and 60 min
(n = 4 for each group) after injection. Whole blood, tumor, and other
major organs and tissues were excised and wet-weighed. Radioactivity
in each sample was measured using a Wizard2 2480 gamma counter
(PerkinElmer, Woodbridge, Ontario, Canada), and radioactivity up-
take was expressed as percent injected dose per gram (%ID/g).
PET Imaging
For PET imaging, Capan-1 tumor-bearingmice were injected intrave-
nously with 18F-hyAPTA-12 (7.4 ± 0.5 MBq, 300 pmol) or 18F-FDG
Figure 6. H&E, Ki67, and TUNEL Analysis of Tumor
Tissues of Capan-1 Tumor-Bearing Mice after
Treatment with APTA-12
H&E stain showed that more mitotic figures and necrosis
were noted in DPBS-treated group. Black arrows indicate
mitotic figures. Ki67-positive cells were quantified by
counting five fields from each tumor. The results indicated
significant reduction of Ki67 expression in the APTA-12-
treated mice (p < 0.05). APTA-12 treatment-induced
apoptosis shown by TUNEL staining of Capan-1 tumors.
Quantification of TUNEL-positive cells shows that inhibi-
tion of APTA-12 led to a four-fold increase in apoptotic
cells (p < 0.05). Magnification, 200.
www.moleculartherapy.org(5.6 ± 0.5 MBq) via tail vein. PET imaging was performed using an
Inveon microPET scanner (Siemens, Knoxville, TN, USA). PET im-
ages were acquired for 10 min using the static acquisition mode at
60 min after injection, and images were reconstructed by a 3-dimen-
sional ordered-subsets expectation maximum (OSEM) algorithm.
Quantiﬁcation analysis was performed as previously reported.55
In Vivo Tumor Growth Inhibition
The in vivo therapeutic effect of APTA-12 was evaluated in mice
bearing Capan-1 xenografts. When the tumor volumes reached
approximately 100 mm3, Capan-1 tumor-bearing mice were
randomly separated into four groups (n = 8 per group) as follows:
group I, tumor control (DPBS); group II, gemcitabine 6 mg/kg; group
III, APTA-12 100 mg/kg; group IV, AS1411 100 mg/kg. The absolute
amount of gemcitabine in 100 mg/kg APTA-12 was equivalent to
6 mg/kg gemcitabine. Gemcitabine, APTA-12, and AS1411 were dis-
solved in DPBS and then injected intravenously into mice every other
day eight times. Body weight and tumor volume were measured every
other day. Tumor volume was determined according to the following
formula: tumor volume (mm3) = a  b2  0.52, where a was the
longest diameter and b was the shortest diameter. The mice were
sacriﬁced on day 22, and the tumors were excised, weighed, and
photographed.
Hematological and Biochemical Parameters
Prior to tumor dissection, blood samples were collected through car-
diac puncture under the isoﬂurane anesthesia on day 22.Whole blood
was collected in an EDTA-coated Microtainer tube (BD Biosciences,
Franklin Lakes, NJ) for complete blood counts (CBC), and centri-
fuged at 2,500  g for 10 min. Hematological parameters were
analyzed using HEMAVET 950 hematology system (Drew Scientiﬁc,
Waterbury, CT).
Blood was collected in Microtainer Serum Separator tubes (BD Bio-
sciences), and serum was obtained after centrifugation at 2,000  g
for 20 min. The biochemical parameter testing was performed using
an automated biochemistry analyzer (FUJI DRI-CHEM 4000i, Fuji,
Tokyo, Japan). Liver function was evaluated based on the serum levelsof AST, ALT, and ALP. Renal function was analyzed by serum creat-
inine and BUN.
Histological and Immunohistochemical Analysis
The tumors were ﬁxed in 4% formalin, embedded in parafﬁn, and
sectioned at 4- to 5-mm thickness. The sections were deparafﬁnized,
dehydrated, and stained with H&E for histological analysis. Tumor
cell proliferation was measured by Ki67 staining with anti-Ki67 anti-
body (Abcam, Cambridge, MA) as described previously.56 The detec-
tion of apoptotic cells in tumor tissue sections was performed using
the TACS 2TdT-DAB In Situ Apoptosis Detection Kit (Trevigen, Gai-
thersburg, MD) following the manufacturer’s instructions. Cell nuclei
were counterstained with methyl green solution. The number of ter-
minal deoxynucleotidyl TUNEL and Ki67-positive cells was counted
by double-blind evaluations. TUNEL and Ki67-positive cells were
quantiﬁed manually using ImageJ software according to a method
described previously.57
Statistical Analysis
Quantitative data were expressed as mean ± SD. Data were compared
using one-way ANOVA and Student’s t test. p values < 0.05 were
considered statistically signiﬁcant.
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